The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

• Published in: British journal of clinical pharmacology Vol. 86; no. 12; pp. 2507 - 2518
• Main Authors: Nnane, Ivo, Frederick, Bart, Yao, Zhenling, Raible, Donald, Shu, Cathye, Badorrek, Philipp, Boer, Maarten, Branigan, Patrick, Duffy, Karen, Baribaud, Frédéric, Fink, Damien, Yang, Tong‐Yuan, Xu, Zhenhua
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 01.12.2020
• Subjects: Antibodies, Monoclonal - therapeutic use; asthma; Asthma - drug therapy; atopic dermatitis; CNTO 7160; Dermatitis, Atopic - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Healthy Volunteers; Humans; Interleukin-1 Receptor-Like 1 Protein; interleukin‐33 receptor; monoclonal antibody; Original; pharmacodynamics; atopic dermatitis; asthma; monoclonal antibody; CNTO 7160; interleukin-33 receptor; pharmacodynamics
• ISSN: 0306-5251; 1365-2125; 1365-2125
• DOI: 10.1111/bcp.14361

Aims To assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of CNTO 7160, an anti‐interleukin‐33 receptor (IL‐33R) monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis (AD). Methods In Part 1 of this Phase I, randomized, double‐blind, placebo‐controlled study, healthy subjects (n = 68) received single ascending intravenous (IV) CNTO 7160 dose (0.001 to 10 mg/kg) or placebo. In Part 2, patients with mild asthma (n = 24) or mild AD (n = 15) received 3 biweekly IV CNTO 7160 doses (3 or 10 mg/kg) or placebo. Results CNTO 7160 was generally well tolerated, with 1 serious adverse event of severe cellulitis reported (AD, CNTO 7160, 3 mg/kg). CNTO 7160 exhibited nonlinear PK (0.01–10 mg/kg). Mean clearance decreased with increasing dose (2.43 to 18.03 mL/d/kg). CNTO 7160 PK was similar between healthy subjects and patients with asthma or AD (3 or 10 mg/kg). Free sIL‐33R suppression was rapid and dose dependent. Ex vivo inhibition of p38 phosphorylation of basophils was dose‐dependent (1–10 mg/kg) and sustained inhibition (≥75%) was observed at higher doses (3 or 10 mg/kg). PK/PD modelling and simulation suggests that 1 mg/kg IV every 2 weeks provides adequate systemic drug exposure for sustained inhibition of p38 phosphorylation of basophils. Despite confirmation of target engagement, no apparent CNTO 7160 clinical activity was observed in patients (asthma or AD). Conclusion This first‐in‐human study provides PK, PD and safety data, supporting further clinical investigation of CNTO 7160 in patients with asthma and AD.